Press release
Key Trend Reshaping the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market in 2025: Breakthroughs In Immune Modulation For The Market
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size
The increasing healthcare expenditure is expected to propel the growth of the chronic inflammatory demyelinating polyneuropathy (CIDP) market. Rising healthcare expenditure is a result of increased investments in medical infrastructure, demand for advanced treatments, expanded insurance coverage, and efforts to improve healthcare access. This increased spending facilitates better diagnosis and management of CIDP, a rare neurological disorder, through improved treatments and better patient outcomes. In May 2024, the Office for National Statistics in the UK reported a 5.6% increase in healthcare spending from 2022 to 2023. As healthcare expenditure continues to rise, it will drive the growth of the CIDP market by enhancing access to effective therapies.
Get Your Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Report Here:
https://www.thebusinessresearchcompany.com/report/chronic-inflammatory-demyelinating-polyneuropathy-cidp-global-market-report
What is the projected compound annual growth rate (CAGR) of the chronic inflammatory demyelinating polyneuropathy (cidp) market from 2025 to 2034, and what factors influence it?
The chronic inflammatory demyelinating polyneuropathy (CIDP) market has seen significant growth, expected to increase from $2.10 billion in 2024 to $2.38 billion in 2025, with a CAGR of 8.4%. Growth has been driven by an aging population, improvements in treatment options, increased awareness and early diagnosis, advancements in immunology and autoimmune research, and a rising prevalence of autoimmune diseases.
The chronic inflammatory demyelinating polyneuropathy (CIDP) market is expected to see steady growth, reaching $3.11 billion in 2029 at a CAGR of 8.1%. Factors contributing to this growth include an aging global population, increasing focus on rare diseases and autoimmune disorders, improved healthcare access, patient advocacy initiatives, and enhanced healthcare infrastructure. Notable trends in this sector include a rising prevalence of CIDP, advancements in treatment options, intensified research and development efforts, the emergence of biosimilar therapies, and the evolution of personalized medicine.
Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21144&type=smp
How are the latest trends influencing the growth of the chronic inflammatory demyelinating polyneuropathy (cidp) market?
Leading companies in the chronic inflammatory demyelinating polyneuropathy (CIDP) market are advancing therapies like intravenous immunoglobulin (IVIG) to improve treatment efficacy, patient outcomes, and immune modulation for managing CIDP. IVIG therapy involves infusing concentrated antibodies from healthy donors to help regulate the immune system and reduce inflammation in autoimmune conditions. For example, in January 2024, Takeda Pharmaceutical Company Limited, a Japan-based biopharmaceutical company, received FDA approval for GAMMAGARD LIQUID as an IVIG therapy for adults with CIDP. This approval allows its use as an induction therapy, beginning with an initial dose followed by maintenance doses to support long-term disease management and enhance neuromuscular function.
What are the major segments of the chronic inflammatory demyelinating polyneuropathy (cidp) market and their role in driving growth?
The chronic inflammatory demyelinating polyneuropathy (CIDP) market covered in this report is segmented -
1) By Treatment: Intravenous Immunoglobulin, Corticosteroids, Plasmapheresis, Physiotherapy, Other Treatments
2) By Route Of Administration: Intravenous, Oral, Other Routes Of Administration
3) By Diagnosis: Electrodiagnostic Testing, Nerve Conduction, Electromyography (EMG), Spinal Fluid Analysis, Other Diagnosis
4) By Distribution Channel: Hospitals, Pharmacies, Online Pharmacies, Specialty Clinics
5) By End User: Hospitals, Research Institutions, Homecare Settings
Subsegments:
1) By Intravenous Immunoglobulin (IVIG): Standard IVIG Therapy, High-Dose IVIG Therapy
2) By Corticosteroids: Oral Corticosteroids, Intravenous Corticosteroids
3) By Plasmapheresis: Single-Exchange Plasmapheresis, Multiple-Exchange Plasmapheresis
4) By Physiotherapy: Muscle Strengthening Exercises, Balance And Coordination Therapy
5) By Other Treatments: Immunosuppressive Agents, Monoclonal Antibodies
Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21144
Which regions are key players in the growth of the chronic inflammatory demyelinating polyneuropathy (cidp) market?
North America was the largest region in the chronic inflammatory demyelinating polyneuropathy (CIDP) market in 2024. The regions covered in the chronic inflammatory demyelinating polyneuropathy (CIDP) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Who are the key firms paving the way for growth in the chronic inflammatory demyelinating polyneuropathy (cidp) market?
Major companies operating in the chronic inflammatory demyelinating polyneuropathy (CIDP) market are Pfizer Inc., Johnson & Johnson, Sanofi SA, Novartis AG, Takeda Pharmaceutical Company Limited, Baxter International Inc., CSL Behring (CSL Limited), Grifols S.A., Sun Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Octapharma AG, Cipla Inc., Hikma Pharmaceuticals plc, Halozyme Therapeutics, Hualan Biological Engineering Inc, argenx SE, Hovione, Nihon Pharmaceutical Co. Ltd., Bio Products Laboratory Ltd., AdvaCare Pharma.
Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/sample.aspx?id=21144&type=smp
What Is Covered In The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Global Market Report?
•Market Size Forecast: Examine the chronic inflammatory demyelinating polyneuropathy (cidp) market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the chronic inflammatory demyelinating polyneuropathy (cidp) market for a structured understanding.
•Key Players Overview: Analyze major players in the chronic inflammatory demyelinating polyneuropathy (cidp) market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the chronic inflammatory demyelinating polyneuropathy (cidp) market.
•Segment Contributions: Evaluate how different segments drive overall growth in the chronic inflammatory demyelinating polyneuropathy (cidp) market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the chronic inflammatory demyelinating polyneuropathy (cidp) market.
•Industry Challenges: Identify potential risks and obstacles affecting the chronic inflammatory demyelinating polyneuropathy (cidp) market.
•Competitive Landscape: Review strategic developments in the chronic inflammatory demyelinating polyneuropathy (cidp) market, including expansions, agreements, and new product launches.
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Key Trend Reshaping the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market in 2025: Breakthroughs In Immune Modulation For The Market here
News-ID: 3934481 • Views: …
More Releases from The Business Research Company
Top Trends Transforming the Fluoropolymer Films Market Landscape in 2025: Techno …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the Fluoropolymer Films Industry Market Size Be by 2025?
The fluoropolymer films market has seen strong growth recently. It will expand from $2.5 billion in 2024 to $2.65 billion in 2025 at a CAGR of 5.7%. Growth drivers in the past included high thermal stability, electronics manufacturing…
Driving Digitally Printed Wallpaper Market Growth in 2025: The Role of Rising Ur …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Digitally Printed Wallpaper Market Size Growth Forecast: What to Expect by 2025?
The digitally printed wallpaper market has expanded rapidly in recent years. It will grow from $9.13 billion in 2024 to $10.26 billion in 2025, at a CAGR of 12.4%. Historic growth was fueled by interior design preferences,…
Top Market Shifts Transforming the Biodegradable Paper and Plastic Packaging Mar …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Biodegradable Paper and Plastic Packaging Market Through 2025?
Over the past few years, we've witnessed a significant expansion in the size of the biodegradable paper and plastic packaging market. It is projected to rise from $12.97 billion in 2024 to $14.12 billion…
Acrylic Rubber Market Landscape to 2034: Key Forces Shaping the Next Decade of G …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Acrylic Rubber Market Size By 2025?
The acrylic rubber industry has seen robust growth in the past few years. The market value, which is projected to escalate from $1.63 billion in 2024 to $1.74 billion in 2025, implies a compound annual growth rate (CAGR) of…
More Releases for CIDP
CIDP Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landsca …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Chronic Inflammatory Demyelinating Polyneuropathy pipeline constitutes 2+ key companies continuously working towards developing 4+ Chronic Inflammatory Demyelinating Polyneuropathy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Chronic Inflammatory Demyelinating Polyneuropathy Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across…
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Growth, Trends, …
Introduction
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a rare autoimmune disorder characterized by progressive weakness and impaired sensory function in the arms and legs due to damage to the myelin sheath surrounding peripheral nerves. Though uncommon, CIDP significantly affects patient quality of life and requires long-term management, often involving immunotherapy, corticosteroids, and plasma exchange.
Over the past decade, improved diagnostic capabilities, greater awareness of rare neurological diseases, and advancements in immunoglobulin therapies…
CIDP Market Emerging Trends and Growth Prospects 2034
Introduction
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) is a rare, immune-mediated neuropathy characterized by progressive or relapsing weakness, sensory loss, and impaired reflexes due to demyelination of peripheral nerves. Unlike acute Guillain-Barré syndrome, CIDP evolves over at least eight weeks and, without timely treatment, can lead to significant long-term disability. The condition encompasses typical CIDP and several clinical variants (e.g., MADSAM/Lewis-Sumner, DADS, pure motor, pure sensory), each with nuanced diagnostic and therapeutic…
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): Market Insights and Co …
The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market sector is undergoing significant transformation, with substantial growth and technological advancements expected by 2031. According to a new in-depth market research report, the sector is poised for expansion, driven by various factors such as market size, share, and emerging trends.
This comprehensive report provides key insights into the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market, exploring critical market segmentation and definitions. It highlights the essential…
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Treatment Market 2024-2 …
Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market is an uncommon autoimmune disorder affecting the peripheral nervous system. It manifests through the progressive weakening of muscles and the loss of sensation in extremities. The CIDP treatment market has shown consistent growth and is poised for significant expansion in the forthcoming years. In this comprehensive blog post, we will delve into the current scenario, regulatory framework, market dynamics, supplier landscape, drug distribution model,…
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Market Insights …
The market for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) was valued USD 968 Million in 2017 which is anticipated to reach USD 2,020.6 Million by 2030.
The total number of CIDP patients in the 7MM is projected to reach 55,113 by 2030 from 46,027 in 2019. The U.S. has the highest incidences of CIDP in the 7MM. In 2019, as per the data studied by Report Ocean, there were approximately 29,000…
